Eli Lilly Completes Acquisition of AtaiBeckley

09:23 AM EDT, 09/11/2026 (MT Newswires) -- Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. The acquisition includes BPL-003, an investigational program for treatment-resistant depression, Lilly said. The deal was approved by AtaiBeckley shareholders at a special meeting held prior to closing, Lilly said.